Table 1 Potentially therapeutics prioritized by LLM with cross-validation
Drug Name | Graph Model | LLM-based Analysis | Hazard Ratio(p) | Clinical Trial Count (ID) | |||||
|---|---|---|---|---|---|---|---|---|---|
\({|T}_{i}|\) | \({R}_{u}(i)\) | \({R}_{p}(i)\) | \({R}_{n}(i)\) | Criterion 1 | Criterion 2 | ||||
Istradefylline | TxGNN | 4 | 0.50 | 0.25 | 0.25 | Potentially therapeutic | Potentially therapeutic | 0.02 (0.95) | 0 |
Chlorpromazine* | TxGNN | 23 | 0.91 | 0.04 | 0.04 | Potentially therapeutic | Potentially therapeutic | 0.001 (0.93) | 2(NCT02309723,NCT00975481) |
Pimavanserin* | TxGNN | 8 | 0.88 | 0.12 | 0 | Potentially therapeutic | Potentially therapeutic | 12.60 (0.01) | 4(NCT02992132,NCT03325556,NCT03118947,NCT02035553) |
Droxidopa | TxGNN | 6 | 0.50 | 0.50 | 0 | Potentially therapeutic | Potentially therapeutic | 0.00 (0.90) | 0 |
Apomorphine* | TxGNN | 9 | 0.89 | 0.11 | 0 | Potentially therapeutic | Potentially therapeutic | 67.27 (<0.001) | 2(NCT03837067,NCT04653584) |
Neostigmine | CompGCN | 5 | 0.80 | 0.20 | 0 | Potentially therapeutic | Potentially therapeutic | <0.001 (0.92) | 0 |
Carbamazepine | CompGCN | 39 | 0.82 | 0.15 | 0.03 | Potentially therapeutic | Potentially therapeutic | 0.94 (0.82) | 0 |
Memantine* | CompGCN | 200 | 0.77 | 0.19 | 0.04 | Potentially therapeutic | Potentially therapeutic | 0.59 (<0.001) | 97(NCT00545974,NCT01626391,NCT01409694,NCT00353665,NCT05669365) |
Haloperidol | CompGCN | 30 | 0.80 | 0.03 | 0.17 | Potentially adverse effect | Potentially therapeutic | <0.001 (0.89) | 4(NCT02309723,NCT00009217,NCT00000179,NCT00249145) |
Riluzole* | CompGCN | 7 | 0.71 | 0.29 | 0 | Potentially therapeutic | Potentially therapeutic | 1.92 (0.19) | 3(NCT00353665,NCT03605667,NCT01703117) |
Minocycline* | CompGCN | 24 | 0.58 | 0.33 | 0.08 | Potentially therapeutic | Potentially therapeutic | 1.24 (0.57) | 1(NCT01463384) |
Magnesium* | CompGCN | 200 | 0.97 | 0.03 | 0 | Potentially therapeutic | Potentially therapeutic | NA | 18(NCT04656860,NCT05728229,NCT00490568,NCT04606420,NCT04251182) |
Carmustine | RLR | 2 | 0.50 | 0.50 | 0 | Potentially therapeutic | Potentially therapeutic | NA | 0 |
Testosterone* | RLR | 103 | 0.94 | 0.05 | 0.01 | Potentially therapeutic | Potentially therapeutic | 0.84 (0.27) | 5(NCT00392912,NCT02727699,NCT02018497,NCT00539305,NCT00000177) |
Naproxen* | RLR | 37 | 0.76 | 0.05 | 0.19 | Potentially adverse effect | Potentially therapeutic | 0.94 (0.38) | 4(NCT00007189,NCT01417130,NCT02702817,NCT00004845) |
Doxycycline* | RLR | 90 | 0.91 | 0.07 | 0.02 | Potentially therapeutic | Potentially therapeutic | 0.95 (0.81) | 4(NCT00439166,NCT04846335,NCT00715858,NCT00692588) |
Histamine* | RLR | 61 | 0.98 | 0.02 | 0 | Potentially therapeutic | Potentially therapeutic | NA | 8(NCT01268020,NCT01505504,NCT00987220,NCT06169826,NCT01009255) |
